FDA expands approval for Otsuka's antipsychotic drug: 3 things to know - Becker's Hospital Review

Here are three things to know.

Abilify Maintena is a once-daily injectable antipsychotic drug for intramuscular use.

The agency first approved the drug in 2013 to treat schizophrenia.

Abilify Maintena may now be used as a monotherapy for adults with bipolar I disorder.

More articles on supply chain:
Merck warns of drug delays after ‘NotPetya’ cyberattack: 3 things to know
6 must-reads for supply chain leaders this week
Drug packager recalls muscle spasm, Parkinson’s drugs over labeling errors

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Next Up in Supply Chain

FDA creates new infection diagnostic device category

The FDA has created a new category of infection diagnostic devices designed to detect microorganism nucleic acids and antimicrobial resistance…

FDA alerts hospitals to anesthesia machine issue

The FDA has issued an early alert for certain Draeger anesthesia workstations tied to a manufacturing issue that could cause…

Louisiana hospital taps Medline as prime vendor

Baton Rouge, La.-based Woman’s Hospital has expanded its prime vendor agreement with Medline to include laboratory products and distribution services.…

Next Up in Supply Chain

Join the 500,000+ healthcare executives who start their day with Becker’s